Credit Agricole S A lowered its stake in shares of Colgate-Palmolive Company (NYSE:CL - Free Report) by 7.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,295,271 shares of the company's stock after selling 100,532 shares during the quarter. Credit Agricole S A owned approximately 0.16% of Colgate-Palmolive worth $121,367,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in CL. Nuveen LLC bought a new position in Colgate-Palmolive during the first quarter worth $217,593,000. Goldman Sachs Group Inc. lifted its stake in Colgate-Palmolive by 34.5% during the first quarter. Goldman Sachs Group Inc. now owns 7,980,387 shares of the company's stock worth $747,762,000 after purchasing an additional 2,045,191 shares during the last quarter. Deutsche Bank AG lifted its stake in Colgate-Palmolive by 35.6% during the fourth quarter. Deutsche Bank AG now owns 6,922,994 shares of the company's stock worth $629,369,000 after purchasing an additional 1,816,865 shares during the last quarter. Diamond Hill Capital Management Inc. lifted its stake in Colgate-Palmolive by 45.0% during the first quarter. Diamond Hill Capital Management Inc. now owns 5,562,968 shares of the company's stock worth $521,250,000 after purchasing an additional 1,727,105 shares during the last quarter. Finally, Castlekeep Investment Advisors LLC bought a new position in Colgate-Palmolive during the fourth quarter worth $111,738,000. 80.41% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Morgan Stanley reduced their price objective on Colgate-Palmolive from $104.00 to $96.00 and set an "overweight" rating on the stock in a research note on Monday, August 4th. JPMorgan Chase & Co. reduced their price objective on Colgate-Palmolive from $99.00 to $95.00 and set an "overweight" rating on the stock in a research note on Monday, August 4th. UBS Group cut their target price on Colgate-Palmolive from $109.00 to $106.00 and set a "buy" rating on the stock in a research note on Thursday, July 17th. Barclays raised their target price on Colgate-Palmolive from $86.00 to $87.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Finally, Wall Street Zen cut Colgate-Palmolive from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Colgate-Palmolive presently has an average rating of "Moderate Buy" and a consensus target price of $98.92.
View Our Latest Stock Analysis on Colgate-Palmolive
Colgate-Palmolive Stock Performance
CL stock traded down $0.5010 during mid-day trading on Friday, reaching $85.7790. The company had a trading volume of 4,087,413 shares, compared to its average volume of 5,056,872. The stock has a market capitalization of $69.33 billion, a P/E ratio of 24.10, a P/E/G ratio of 4.47 and a beta of 0.35. The company has a quick ratio of 0.57, a current ratio of 0.89 and a debt-to-equity ratio of 6.79. Colgate-Palmolive Company has a one year low of $82.40 and a one year high of $109.30. The stock's 50-day simple moving average is $87.60 and its two-hundred day simple moving average is $89.93.
Colgate-Palmolive (NYSE:CL - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.89 by $0.03. The company had revenue of $5.11 billion for the quarter, compared to analyst estimates of $5.03 billion. Colgate-Palmolive had a return on equity of 377.63% and a net margin of 14.55%.The company's quarterly revenue was up 1.0% compared to the same quarter last year. During the same period last year, the company earned $0.91 earnings per share. Research analysts anticipate that Colgate-Palmolive Company will post 3.75 EPS for the current year.
Colgate-Palmolive Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Friday, July 18th were issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend was Friday, July 18th. Colgate-Palmolive's dividend payout ratio (DPR) is 58.43%.
Colgate-Palmolive Profile
(
Free Report)
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
Featured Stories

Before you consider Colgate-Palmolive, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Colgate-Palmolive wasn't on the list.
While Colgate-Palmolive currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.